Are RLYB, VRME, AES Obtaining Fair Deals for their Shareholders? {"summary":"","positive":[],"negative":[],"faq":[]}

#AES #RLYB #VRME Are RLYB, VRME, AES Obtaining Fair Deals for their Shareholders?

www.stocktitan.net/news/AES/are-rlyb-vrme-a...

Are KW, AES, RLYB Obtaining Fair Deals for their Shareholders? {"summary":"","positive":[],"negative":[],"faq":[]}

#KW #AES #RLYB Are KW, AES, RLYB Obtaining Fair Deals for their Shareholders?

www.stocktitan.net/news/KW/are-kw-aes-rlyb-...

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement Rallybio (Nasdaq: RLYB) and Candid Therapeutics have agreed to merge, with the combined company to operate as Candid Therapeutics (Nasdaq: CDRX). The deal includes an oversubscribed private Financing of over $505 million and pro-forma cash of approximately $700 million expected to fund operations through 2030.The Transaction is expected to close in mid-2026, is subject to customary closing conditions, and pre-Transaction Rallybio equityholders are expected to own approximately 3.65% of the combined company.

#RLYB Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

www.stocktitan.net/news/RLYB/rallybio-corpo...

Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program Rallybio (Nasdaq: RLYB) has received a $12.5 million equity milestone payment from Recursion following the initiation of additional preclinical studies for REV102, a potential first-in-class oral ENPP1 inhibitor being developed for hypophosphatasia (HPP).This payment is part of a previously announced agreement where Rallybio sold its interest in the REV102 program to Recursion for up to $25 million. The company remains eligible for an additional $5 million milestone payment upon Phase 1 clinical study initiation, plus low single-digit royalties on future net sales.The non-dilutive capital extends Rallybio's cash runway through 2027, strengthening its financial position as it awaits topline data from the RLYB116 confirmatory PK/PD study.

#RLYB Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program

www.stocktitan.net/news/RLYB/rallybio-recei...

Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates Rallybio (NASDAQ:RLYB) reported Q2 2025 financial results and significant business updates. The company sold its interest in REV102 to Recursion Pharmaceuticals for up to $25 million, including a $7.5 million upfront equity payment. The deal extends cash runway into mid-2027.Key financial metrics include a net loss of $9.7 million ($0.22 per share), reduced from $16.2 million in Q2 2024. R&D expenses decreased to $6.1 million from $12.9 million year-over-year. Cash position stands at $45.7 million as of June 30, 2025.The company's lead program RLYB116 entered a confirmatory PK/PD study, with data readouts expected in Q3 and Q4 2025. However, Rallybio discontinued the RLYB212 program for FNAIT prevention due to inadequate dose concentration achievements in Phase 2 trials.

#RLYB Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates

www.stocktitan.net/news/RLYB/rallybio-repor...

Rallybio's $25M REV102 Sale to Recursion Promises First Oral Treatment for Rare Bone Disease $25M deal includes $7.5M upfront payment, extending cash runway to 2027. First potential oral treatment for hypophosphatasia (HPP) advances. See milestone details.

#RLYB Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

www.stocktitan.net/news/RLYB/rallybio-sells...

Rallybio's $5B Market Opportunity: New Phase 1 Trial Targets Two Untreated Rare Blood Disorders First-in-class C5 inhibitor begins crucial testing for rare blood disorders. Weekly subcutaneous dosing could transform treatment landscape. See trial timeline.

#RLYB Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

www.stocktitan.net/news/RLYB/rallybio-initi...

Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates Rallybio (NASDAQ: RLYB) reported Q1 2025 financial results and business updates. The company is advancing RLYB116 into a confirmatory PK/PD study in Q2 2025, with data readouts expected in H2 2025. Financial highlights include $54.5M in cash providing runway into H1 2027, revenue of $0.2M, and reduced net loss of $9.4M ($0.21/share) compared to $19.0M ($0.47/share) in Q1 2024. The company is implementing a 40% workforce reduction (9 positions) with expected charges of $1.7M. R&D expenses decreased to $5.7M from $12.9M, while G&A expenses reduced to $4.2M from $6.9M. Notable developments include discontinuation of RLYB212 program for FNAIT, ongoing IND-enabling studies for REV102, and continued evaluation of RLYB332 for iron overload diseases.

#RLYB Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates

www.stocktitan.net/news/RLYB/rallybio-repor...

Rallybio Secures 2-Year Cash Runway as Multiple Drug Trials Advance Biotech firm Rallybio reports $65.5M cash position, advancing key drug trials RLYB212 and RLYB116. Q4 developments include J&J collaboration and pipeline expansion.

#RLYB Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

www.stocktitan.net/news/RLYB/rallybio-repor...

Rallybio's RLYB212 Enters Crucial Phase 2 Trial: Revolutionary Protection for At-Risk Pregnancies Rallybio initiates Phase 2 trial of RLYB212 for preventing pregnancy complications, with key data expected Q2-Q3 2025. European study targets FNAIT risk.

#RLYB Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial

www.stocktitan.net/news/RLYB/rallybio-annou...

Rallybio Advances Rare Disease Pipeline: Phase 2 FNAIT Trial Launch, Key Programs Progress Rallybio makes strides in rare disease therapeutics with RLYB212 Phase 2 FNAIT prevention trial, RLYB116 manufacturing improvements, and promising REV102 biomarker data for HPP treatment.

#RLYB Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025

www.stocktitan.net/news/RLYB/rallybio-highl...

Rallybio's ASH Data Shows Breakthrough Potential in Blood Disorder Treatments, Strong Preclinical Results Rallybio presents compelling preclinical data for RLYB212 and RLYB332 at ASH, showing promising efficacy in pregnancy-related blood disorders and iron overload conditions.

#RLYB Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting

#investing #stocks #news

www.stocktitan.net/news/RLYB/rallybio-annou...

Rallybio's RLYB116 Shows Stronger-Than-Reported Efficacy in New Biomarker Analysis | RLYB Stock News Rallybio reveals RLYB116 achieved 10x better complement inhibition than initially measured. Manufacturing improvements made as company prepares for 2025 clinical studies.

#RLYB Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025

#investing #stocks #StockMarket

www.stocktitan.net/news/RLYB/rallybio-to-in...

#RLYB Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women

www.stocktitan.net/news/RLYB/rallybio-annou...

#RLYB Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference

www.stocktitan.net/news/RLYB/rallybio-to-pr...

#RLYB Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor

www.stocktitan.net/news/RLYB/rallybio-to-pr...

#RLYB Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212

www.stocktitan.net/news/RLYB/rallybio-annou...

Just In: ( NASDAQ: #RLYB ) Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting

#StockMarket #News

Breaking News: ( NASDAQ: #RLYB ) Rallybio to Present at Upcoming Investor Conferences

#StockMarket #News